{
  "protocolSection": {
    "identificationModule": {
      "nctId": "NCT04167618",
      "orgStudyIdInfo": {
        "id": "301"
      },
      "organization": {
        "fullName": "Y-mAbs Therapeutics",
        "class": "INDUSTRY"
      },
      "briefTitle": "177Lu-DTPA-Omburtamab Radioimmunotherapy for Recurrent or Refractory Medulloblastoma",
      "officialTitle": "A Phase I/II Dose-escalation and Expansion Cohort Trial of Intracerebroventricular Radioimmunotherapy Using 177Lu-DTPA-Omburtamab in Pediatric and Adolescent Patients With Recurrent or Refractory Medulloblastoma"
    },
    "statusModule": {
      "statusVerifiedDate": "2023-09",
      "overallStatus": "TERMINATED",
      "whyStopped": "Business priorities",
      "expandedAccessInfo": {
        "hasExpandedAccess": false
      },
      "startDateStruct": {
        "date": "2021-09-30",
        "type": "ACTUAL"
      },
      "primaryCompletionDateStruct": {
        "date": "2022-08-11",
        "type": "ACTUAL"
      },
      "completionDateStruct": {
        "date": "2022-08-11",
        "type": "ACTUAL"
      },
      "studyFirstSubmitDate": "2019-11-11",
      "studyFirstSubmitQcDate": "2019-11-14",
      "studyFirstPostDateStruct": {
        "date": "2019-11-19",
        "type": "ACTUAL"
      },
      "resultsFirstSubmitDate": "2023-09-11",
      "resultsFirstSubmitQcDate": "2023-09-11",
      "resultsFirstPostDateStruct": {
        "date": "2023-10-06",
        "type": "ACTUAL"
      },
      "lastUpdateSubmitDate": "2023-09-11",
      "lastUpdatePostDateStruct": {
        "date": "2023-10-06",
        "type": "ACTUAL"
      }
    },
    "sponsorCollaboratorsModule": {
      "responsibleParty": {
        "type": "SPONSOR"
      },
      "leadSponsor": {
        "name": "Y-mAbs Therapeutics",
        "class": "INDUSTRY"
      }
    },
    "oversightModule": {
      "oversightHasDmc": true,
      "isFdaRegulatedDrug": true,
      "isFdaRegulatedDevice": false
    },
    "descriptionModule": {
      "briefSummary": "Children and adolescents diagnosed with medullablastoma and with recurrent or refractory to frontline therapy will be treated with 177Lu-DTPA-omburtamab, which is a radioactive labelling of a murine monoclonal antibody targeting B7-H3.",
      "detailedDescription": "Part 1 is a dose-escalation phase with a 3+3 sequential-group design in which patients will receive a dosimetry dose followed by maximum of two 5-week cycles of treatment doses of intracerebroventricular 177Lu-DTPA-omburtamab.\n\nPart 2 is a cohort-expansion phase in which patients will receive a maximum of five 5-week cycles of intracerebroventricular 177Lu-DTPA-omburtamab at the recommended dose determined in Part 1.\n\nEnd of treatment will take place within 5 weeks after the last cycle and thereafter the patients will be enter the follow-up period. The patients will be followed for up to 2 years after last dose."
    },
    "conditionsModule": {
      "conditions": [
        "Medulloblastoma, Childhood"
      ]
    },
    "designModule": {
      "studyType": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "designInfo": {
        "allocation": "NA",
        "interventionModel": "SINGLE_GROUP",
        "interventionModelDescription": "Patients will receive up to two cycles in Part 1 and up to five cycles in Part 2 of intracerebroventricular 177Lu-DTPA-omburtamab. Safety and efficacy will be investigated during treatment and follow-up period.",
        "primaryPurpose": "TREATMENT",
        "maskingInfo": {
          "masking": "NONE"
        }
      },
      "enrollmentInfo": {
        "count": 2,
        "type": "ACTUAL"
      }
    },
    "armsInterventionsModule": {
      "armGroups": [
        {
          "label": "177Lu-DTPA-omburtamab",
          "type": "EXPERIMENTAL",
          "description": "Intracerebroventricular administration of 177Lu-DTPA-omburtamab for up to two cycles (Part 1) and up to five cycles (Part 2).",
          "interventionNames": [
            "Drug: 177Lu-DTPA-omburtamab"
          ]
        }
      ],
      "interventions": [
        {
          "type": "DRUG",
          "name": "177Lu-DTPA-omburtamab",
          "description": "Biological, radiolabeled DPTA-omburtamab",
          "armGroupLabels": [
            "177Lu-DTPA-omburtamab"
          ]
        }
      ]
    },
    "outcomesModule": {
      "primaryOutcomes": [
        {
          "measure": "Dose Limiting Toxicities (DLTs) Part 1",
          "description": "Summary of DLTs in DLT evaluable subjects.",
          "timeFrame": "Days 1 through 35 in cycle 1"
        }
      ]
    },
    "eligibilityModule": {
      "eligibilityCriteria": "Inclusion Criteria:\n\n* Histologically confirmed diagnosis of medulloblastoma.\n* SHH, Group 3, or Group 4 according to World Health Organisation (WHO) 2016 classification.\n* Recurrent (maximum of 2 recurrences for Part 1 and 1 recurrence for Part 2) or refractory to frontline therapy. Prior frontline or second line therapy may involve surgery, craniospinal irradiation, stereotactic radiosurgery, and multi-agent chemotherapy regimens.\n* Have refractory disease, focal or multifocal recurrent disease, or pure leptomeningeal disease. Cytological or radiographic remission is allowed; however, not simultaneously.\n* Performance status score of 50 to 100 on Lansky (less than 16 years) or Karnofsky (16 years or older) scales.\n* Life expectancy of at least 3 months, as judged by the Investigator.\n* Acceptable hematological status and liver and kidney function.\n\nExclusion Criteria:\n\n* Obstructive or symptomatic communicating hydrocephalus as determined by Ommaya patency/cerebrospinal fluid (CSF) flow study.\n* Residual disease (nodular or linear) measuring \\> 15 mm in the smallest diameter.\n* Ventriculoperitoneal shunts without programmable valves. Ventriculo-atrial or ventriculo-pleural shunts.\n* Grade 4 nervous system disorder. Stable neurological deficits (due to brain tumor or surgery) or hearing loss are allowed.\n* Uncontrolled life-threatening infection.\n* Received radiation therapy less than 3 weeks prior to the screening visit.\n* Received systemic or intrathecal cytotoxic chemotherapy or intrathecal immunotherapy (corticosteroids not included) less than 3 weeks prior to the screening visit.\n* Received any prior anti-B7-H3 treatment.\n* Non-hematologic organ toxicity Grade 3 or above; specifically, any renal, cardiac, hepatic, pulmonary, and gastrointestinal system toxicity.\n* Other significant disease or condition that in the investigator's opinion would exclude the patient from the trial.",
      "healthyVolunteers": false,
      "sex": "ALL",
      "minimumAge": "3 Years",
      "maximumAge": "19 Years",
      "stdAges": [
        "CHILD",
        "ADULT"
      ]
    },
    "contactsLocationsModule": {
      "locations": [
        {
          "facility": "Mayo Clinic",
          "city": "Rochester",
          "state": "Minnesota",
          "zip": "55905",
          "country": "United States",
          "geoPoint": {
            "lat": 44.02163,
            "lon": -92.4699
          }
        },
        {
          "facility": "Memorial Sloan Kettering Cancer Center",
          "city": "New York",
          "state": "New York",
          "zip": "10065",
          "country": "United States",
          "geoPoint": {
            "lat": 40.71427,
            "lon": -74.00597
          }
        },
        {
          "facility": "Doernbecher Children's Hospital",
          "city": "Portland",
          "state": "Oregon",
          "zip": "97239",
          "country": "United States",
          "geoPoint": {
            "lat": 45.52345,
            "lon": -122.67621
          }
        },
        {
          "facility": "M.D. Anderson Cancer Center",
          "city": "Houston",
          "state": "Texas",
          "zip": "77030",
          "country": "United States",
          "geoPoint": {
            "lat": 29.76328,
            "lon": -95.36327
          }
        },
        {
          "facility": "Rigshospitalet, Børneonkologisk afsnit",
          "city": "Copenhagen",
          "zip": "2100",
          "country": "Denmark",
          "geoPoint": {
            "lat": 55.67594,
            "lon": 12.56553
          }
        },
        {
          "facility": "Princess Máxima",
          "city": "Utrecht",
          "zip": "3584CS",
          "country": "Netherlands",
          "geoPoint": {
            "lat": 52.09083,
            "lon": 5.12222
          }
        },
        {
          "facility": "Hospital Universitari Vall d'Hebron",
          "city": "Barcelona",
          "zip": "08035",
          "country": "Spain",
          "geoPoint": {
            "lat": 41.38879,
            "lon": 2.15899
          }
        },
        {
          "facility": "Hospital Sant Joan de Deu de Barcelona",
          "city": "Barcelona",
          "zip": "08950",
          "country": "Spain",
          "geoPoint": {
            "lat": 41.38879,
            "lon": 2.15899
          }
        },
        {
          "facility": "The Royal Marsden Hospital",
          "city": "London",
          "country": "United Kingdom",
          "geoPoint": {
            "lat": 51.50853,
            "lon": -0.12574
          }
        },
        {
          "facility": "Great North Children's Hospital",
          "city": "Newcastle",
          "country": "United Kingdom",
          "geoPoint": {
            "lat": 54.21804,
            "lon": -5.88979
          }
        }
      ]
    }
  },
  "resultsSection": {
    "participantFlowModule": {
      "groups": [
        {
          "id": "FG000",
          "title": "10 mCi 177Lu-DTPA-omburtamab",
          "description": "Intracerebroventricular administration of 10 mCi 177Lu-DTPA-omburtamab for up to two cycles (Part 1).\n\n177Lu-DTPA-omburtamab: Biological, radiolabeled DPTA-omburtamab"
        },
        {
          "id": "FG001",
          "title": "25 mCi 177Lu-DTPA-omburtamab",
          "description": "Intracerebroventricular administration of 25 mCi 177Lu-DTPA-omburtamab for up to two cycles (Part 1).\n\n177Lu-DTPA-omburtamab: Biological, radiolabeled DPTA-omburtamab"
        }
      ],
      "periods": [
        {
          "title": "Overall Study",
          "milestones": [
            {
              "type": "STARTED",
              "achievements": [
                {
                  "groupId": "FG000",
                  "numSubjects": "1"
                },
                {
                  "groupId": "FG001",
                  "numSubjects": "1"
                }
              ]
            },
            {
              "type": "COMPLETED",
              "achievements": [
                {
                  "groupId": "FG000",
                  "numSubjects": "0"
                },
                {
                  "groupId": "FG001",
                  "numSubjects": "0"
                }
              ]
            },
            {
              "type": "NOT COMPLETED",
              "achievements": [
                {
                  "groupId": "FG000",
                  "numSubjects": "1"
                },
                {
                  "groupId": "FG001",
                  "numSubjects": "1"
                }
              ]
            }
          ],
          "dropWithdraws": [
            {
              "type": "Trial terminated by sponsor",
              "reasons": [
                {
                  "groupId": "FG000",
                  "numSubjects": "1"
                },
                {
                  "groupId": "FG001",
                  "numSubjects": "1"
                }
              ]
            }
          ]
        }
      ]
    },
    "baselineCharacteristicsModule": {
      "groups": [
        {
          "id": "BG000",
          "title": "10 mCi 177Lu-DTPA-omburtamab",
          "description": "Intracerebroventricular administration of 10 mCi 177Lu-DTPA-omburtamab for up to two cycles (Part 1).\n\n177Lu-DTPA-omburtamab: Biological, radiolabeled DPTA-omburtamab"
        },
        {
          "id": "BG001",
          "title": "25 mCi 177Lu-DTPA-omburtamab",
          "description": "Intracerebroventricular administration of 25 mCi 177Lu-DTPA-omburtamab for up to two cycles (Part 1).\n\n177Lu-DTPA-omburtamab: Biological, radiolabeled DPTA-omburtamab"
        },
        {
          "id": "BG002",
          "title": "Total",
          "description": "Total of all reporting groups"
        }
      ],
      "denoms": [
        {
          "units": "Participants",
          "counts": [
            {
              "groupId": "BG000",
              "value": "1"
            },
            {
              "groupId": "BG001",
              "value": "1"
            },
            {
              "groupId": "BG002",
              "value": "2"
            }
          ]
        }
      ],
      "measures": [
        {
          "title": "Age, Continuous",
          "paramType": "MEAN",
          "dispersionType": "FULL_RANGE",
          "unitOfMeasure": "years",
          "classes": [
            {
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "15",
                      "lowerLimit": "15",
                      "upperLimit": "15"
                    },
                    {
                      "groupId": "BG001",
                      "value": "8",
                      "lowerLimit": "8",
                      "upperLimit": "8"
                    },
                    {
                      "groupId": "BG002",
                      "value": "11.5",
                      "lowerLimit": "8",
                      "upperLimit": "15"
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "title": "Sex: Female, Male",
          "paramType": "COUNT_OF_PARTICIPANTS",
          "unitOfMeasure": "Participants",
          "classes": [
            {
              "categories": [
                {
                  "title": "Female",
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "0"
                    },
                    {
                      "groupId": "BG001",
                      "value": "0"
                    },
                    {
                      "groupId": "BG002",
                      "value": "0"
                    }
                  ]
                },
                {
                  "title": "Male",
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "1"
                    },
                    {
                      "groupId": "BG001",
                      "value": "1"
                    },
                    {
                      "groupId": "BG002",
                      "value": "2"
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "title": "Race (NIH/OMB)",
          "paramType": "COUNT_OF_PARTICIPANTS",
          "unitOfMeasure": "Participants",
          "classes": [
            {
              "categories": [
                {
                  "title": "American Indian or Alaska Native",
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "0"
                    },
                    {
                      "groupId": "BG001",
                      "value": "0"
                    },
                    {
                      "groupId": "BG002",
                      "value": "0"
                    }
                  ]
                },
                {
                  "title": "Asian",
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "0"
                    },
                    {
                      "groupId": "BG001",
                      "value": "0"
                    },
                    {
                      "groupId": "BG002",
                      "value": "0"
                    }
                  ]
                },
                {
                  "title": "Native Hawaiian or Other Pacific Islander",
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "0"
                    },
                    {
                      "groupId": "BG001",
                      "value": "0"
                    },
                    {
                      "groupId": "BG002",
                      "value": "0"
                    }
                  ]
                },
                {
                  "title": "Black or African American",
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "0"
                    },
                    {
                      "groupId": "BG001",
                      "value": "0"
                    },
                    {
                      "groupId": "BG002",
                      "value": "0"
                    }
                  ]
                },
                {
                  "title": "White",
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "1"
                    },
                    {
                      "groupId": "BG001",
                      "value": "1"
                    },
                    {
                      "groupId": "BG002",
                      "value": "2"
                    }
                  ]
                },
                {
                  "title": "More than one race",
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "0"
                    },
                    {
                      "groupId": "BG001",
                      "value": "0"
                    },
                    {
                      "groupId": "BG002",
                      "value": "0"
                    }
                  ]
                },
                {
                  "title": "Unknown or Not Reported",
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "0"
                    },
                    {
                      "groupId": "BG001",
                      "value": "0"
                    },
                    {
                      "groupId": "BG002",
                      "value": "0"
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "title": "Region of Enrollment",
          "paramType": "NUMBER",
          "unitOfMeasure": "participants",
          "classes": [
            {
              "title": "United States",
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "1"
                    },
                    {
                      "groupId": "BG001",
                      "value": "0"
                    },
                    {
                      "groupId": "BG002",
                      "value": "1"
                    }
                  ]
                }
              ]
            },
            {
              "title": "Denmark",
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "0"
                    },
                    {
                      "groupId": "BG001",
                      "value": "1"
                    },
                    {
                      "groupId": "BG002",
                      "value": "1"
                    }
                  ]
                }
              ]
            }
          ]
        }
      ]
    },
    "outcomeMeasuresModule": {
      "outcomeMeasures": [
        {
          "type": "PRIMARY",
          "title": "Dose Limiting Toxicities (DLTs) Part 1",
          "description": "Summary of DLTs in DLT evaluable subjects.",
          "reportingStatus": "POSTED",
          "paramType": "COUNT_OF_PARTICIPANTS",
          "unitOfMeasure": "Participants",
          "timeFrame": "Days 1 through 35 in cycle 1",
          "groups": [
            {
              "id": "OG000",
              "title": "10 mCi 177Lu-DTPA-omburtamab",
              "description": "Intracerebroventricular administration of 10 mCi 177Lu-DTPA-omburtamab for up to two cycles (Part 1).\n\n177Lu-DTPA-omburtamab: Biological, radiolabeled DPTA-omburtamab"
            },
            {
              "id": "OG001",
              "title": "25 mCi 177Lu-DTPA-omburtamab",
              "description": "Intracerebroventricular administration of 25 mCi 177Lu-DTPA-omburtamab for up to two cycles (Part 1).\n\n177Lu-DTPA-omburtamab: Biological, radiolabeled DPTA-omburtamab"
            }
          ],
          "denoms": [
            {
              "units": "Participants",
              "counts": [
                {
                  "groupId": "OG000",
                  "value": "1"
                },
                {
                  "groupId": "OG001",
                  "value": "1"
                }
              ]
            }
          ],
          "classes": [
            {
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "0"
                    },
                    {
                      "groupId": "OG001",
                      "value": "1"
                    }
                  ]
                }
              ]
            }
          ]
        }
      ]
    },
    "adverseEventsModule": {
      "frequencyThreshold": "0",
      "timeFrame": "From 1st dose to 5 weeks after last dose, up to 10 weeks (2 cycles).",
      "eventGroups": [
        {
          "id": "EG000",
          "title": "10 mCi 177Lu-DTPA-omburtamab",
          "description": "Intracerebroventricular administration of 10 mCi 177Lu-DTPA-omburtamab for up to two cycles (Part 1).\n\n177Lu-DTPA-omburtamab: Biological, radiolabeled DPTA-omburtamab",
          "deathsNumAffected": 0,
          "deathsNumAtRisk": 1,
          "seriousNumAffected": 1,
          "seriousNumAtRisk": 1,
          "otherNumAffected": 0,
          "otherNumAtRisk": 1
        },
        {
          "id": "EG001",
          "title": "25 mCi 177Lu-DTPA-omburtamab",
          "description": "Intracerebroventricular administration of 25 mCi 177Lu-DTPA-omburtamab for up to two cycles (Part 1).\n\n177Lu-DTPA-omburtamab: Biological, radiolabeled DPTA-omburtamab",
          "deathsNumAffected": 0,
          "deathsNumAtRisk": 1,
          "seriousNumAffected": 0,
          "seriousNumAtRisk": 1,
          "otherNumAffected": 1,
          "otherNumAtRisk": 1
        }
      ],
      "seriousEvents": [
        {
          "term": "Partial seizures",
          "organSystem": "Nervous system disorders",
          "sourceVocabulary": "MedDRA 24.1",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 1
            },
            {
              "groupId": "EG001",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 1
            }
          ]
        }
      ],
      "otherEvents": [
        {
          "term": "Alanine aminotransferase increased",
          "organSystem": "Investigations",
          "sourceVocabulary": "MedDRA 24.1",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 1
            },
            {
              "groupId": "EG001",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 1
            }
          ]
        },
        {
          "term": "Blood albumin decreased",
          "organSystem": "Investigations",
          "sourceVocabulary": "MedDRA 24.1",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 1
            },
            {
              "groupId": "EG001",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 1
            }
          ]
        },
        {
          "term": "Neutrophil count decreased",
          "organSystem": "Investigations",
          "sourceVocabulary": "MedDRA 24.1",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 1
            },
            {
              "groupId": "EG001",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 1
            }
          ]
        },
        {
          "term": "Platelet count decreased",
          "organSystem": "Investigations",
          "sourceVocabulary": "MedDRA 24.1",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 1
            },
            {
              "groupId": "EG001",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 1
            }
          ]
        },
        {
          "term": "White blood cell count decreased",
          "organSystem": "Investigations",
          "sourceVocabulary": "MedDRA 24.1",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 1
            },
            {
              "groupId": "EG001",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 1
            }
          ]
        }
      ]
    },
    "moreInfoModule": {
      "limitationsAndCaveats": {
        "description": "The trial was terminated after 2 subjects due to a business strategy decision. At this point the maximum tolerated dose was not established."
      },
      "certainAgreement": {
        "piSponsorEmployee": false,
        "restrictiveAgreement": false
      },
      "pointOfContact": {
        "title": "Joris Wilms",
        "organization": "Y-mAbs Therapeutics",
        "email": "clinicaltrials@ymabs.com",
        "phone": "+4570261414"
      }
    }
  },
  "documentSection": {
    "largeDocumentModule": {
      "largeDocs": [
        {
          "typeAbbrev": "Prot_SAP",
          "hasProtocol": true,
          "hasSap": true,
          "hasIcf": false,
          "label": "Study Protocol and Statistical Analysis Plan",
          "date": "2022-02-25",
          "uploadDate": "2023-09-11T03:34",
          "filename": "Prot_SAP_000.pdf",
          "size": 881428
        }
      ]
    }
  },
  "derivedSection": {
    "miscInfoModule": {
      "versionHolder": "2026-02-04"
    },
    "conditionBrowseModule": {
      "meshes": [
        {
          "id": "D008527",
          "term": "Medulloblastoma"
        }
      ],
      "ancestors": [
        {
          "id": "D005910",
          "term": "Glioma"
        },
        {
          "id": "D018302",
          "term": "Neoplasms, Neuroepithelial"
        },
        {
          "id": "D017599",
          "term": "Neuroectodermal Tumors"
        },
        {
          "id": "D009373",
          "term": "Neoplasms, Germ Cell and Embryonal"
        },
        {
          "id": "D009370",
          "term": "Neoplasms by Histologic Type"
        },
        {
          "id": "D009369",
          "term": "Neoplasms"
        },
        {
          "id": "D018242",
          "term": "Neuroectodermal Tumors, Primitive"
        },
        {
          "id": "D009375",
          "term": "Neoplasms, Glandular and Epithelial"
        },
        {
          "id": "D009380",
          "term": "Neoplasms, Nerve Tissue"
        }
      ]
    }
  },
  "hasResults": true
}